Harnessing Single-Cell Technologies in the Search for New Therapies for Diamond–Blackfan Anemia Syndrome
Experimental Hematology · 2024-07 · 135 · 104235
DOI: 10.1016/j.exphem.2024.104235 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Hematology, 2024-07. Verfasst von Deena Iskander und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, Department of Immunology and Inflammation, Imperial College, London, United Kingdom; Department of Paediatric Haematology, St…. Hauptthemen laut MEDLINE: Anemia, Diamond-Blackfan, Single-Cell Analysis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, American Society of Hematology, European Hematology Association.
Abstract (Originalsprache)
The emergence of multiomic single-cell technologies over the last decade has led to improved insights into both normal hematopoiesis and its perturbation in a variety of hematological disorders. Diamond-Blackfan anemia (DBA) syndrome is one such disorder where single-cell assays have helped to delineate the cellular and molecular defects underlying the disease. DBA is caused by heterozygous loss-of-function germline variants in genes encoding ribosomal proteins (RPs). Despite the widespread role of ribosomes in hematopoiesis, the most frequent and severe cytopenia in DBA is anemia. In this review we discussed how single-cell studies, including clonogenic cell culture assays, fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (scRNA-seq), have led to insights into the pathogenesis of DBA. The main therapies are regular blood transfusions, glucocorticoids, or hematopoietic stem cell transplantation (HSCT) but all are associated with significant morbidity and mortality. We will therefore outline how single-cell studies can inform new therapies for DBA. Furthermore, we discussed how DBA serves as a useful model for understanding normal erythropoiesis in terms of its cellular hierarchy, molecular regulation during homeostasis, and response to "stress."
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Haematology, Department of Immunology and Inflammation, Imperial College, London, United Kingdom; Department of Paediatric Haematology, St Mary's Hospital, Imperial College Healthcare Trust, London, United Ki…
- Centre for Haematology, Department of Immunology and Inflammation, Imperial College, London, United Kingdom.
- MRC Molecular Haematology Unit, WIMM, University of Oxford, Oxford, United Kingdom; Department of Paediatrics, Children's Hospital and MHU, WIMM, Oxford University and John Radcliffe Hospital, Oxford, United Kingdom.
Förderung
- National Institute for Health and Care Research
- American Society of Hematology
- European Hematology Association
Zitieren
APA
Iskander, D., Karadimitris, A., & Roberts, I. (2024). Harnessing Single-Cell Technologies in the Search for New Therapies for Diamond–Blackfan Anemia Syndrome. Experimental Hematology, 135, 104235. https://doi.org/10.1016/j.exphem.2024.104235
Vancouver
Iskander D, Karadimitris A, Roberts I. Harnessing Single-Cell Technologies in the Search for New Therapies for Diamond–Blackfan Anemia Syndrome. Experimental Hematology. 2024;135:104235. doi:10.1016/j.exphem.2024.104235
BibTeX
@article{Iskander2024,
author = {Iskander, Deena and Karadimitris, Anastasios and Roberts, Irene},
title = {Harnessing Single-Cell Technologies in the Search for New Therapies for Diamond–Blackfan Anemia Syndrome},
journal = {Experimental Hematology},
year = {2024},
volume = {135},
pages = {104235},
doi = {10.1016/j.exphem.2024.104235}
}
EUVIMED